CRPS Treatment: Neridronate
First and foremost, the FACTS.
Bisphosphonates and CRPS.
ABSTRACT: Neridronate is an amino-bisphosphonate that has been officially approved as a treatment for osteogenesis imperfecta, Paget’s disease of bone and complex regional pain syndrome (CRPS) in Italy. Neridronate is administered either intravenously or intramuscularly; thus, it represents a valid option for both cases with contraindications to the use of oral bisphosphonates and cases with contraindications or an inability to receive an intravenous administration of these drugs. Furthermore, although the official authorized use of neridronate is limited to only 3 bone diseases, many experimental and clinical studies support the rationale for its use and provide evidence of its effectiveness in other
pathologic bone conditions that are characterized by altered bone remodelling.
Internationally, Neridronic acid is the first investigational medicine to receive Breakthrough Therapy Designation for the treatment of CRPS. It was discovered and developed by Abiogen Pharma SpA, Pisa, Italy, where it was patented and recognized by AIFA as the approved therapy for CRPS.
Before and after pictures of Carole’s hand.
Carol was treated for CRPS which affected her left hand causing extreme swelling, pain, burning flares and inability to move the hand. Five months after the treatment, she regained mobility and eventually her hand went perfectly back to normal.
“Neridronate has also been evaluated as a treatment for CRPS-I in a recent large multicentre, randomized, double-blind, placebo-controlled trial. About 82 patients with CRPS-I in either their hand or foot were randomly assigned to receive either an intravenous infusion of 100 mg of neridronate every 3 days for a total of 4 times or the placebo. After 50 days of the last infusion, the placebo group was treated with the same regimen of neridronate. In the double-blind phase, the visual analog scale (VAS) for pain was significantly lower in the neridronate-treated group after 20 days of treatment than in the placebo group and only continued to decrease for the next 20 days in the neridronate group. Oedema, pain induced by passive motion, allodynia, and hyperalgesia were significantly reduced in patients who were treated with neridronate compared with those in patients in the placebo group, and various functional indexes were increased. All neridronate-treated patients and only 45% of the patients who were treated with the placebo discontinued the symptomatic drugs within 2 weeks. The results obtained from patients had previously received the placebo, were subsequently treated with neridronate during the open-extension phase, and were similar to obtained from the neridronate-treated group during the blind phase, as represented by significant reductions in the VAS, oedema, and pain on passive motion; the disappearance of allodynia and hyperalgesia; and an improvement in functional scores after 40 days of follow-up. A complete normalization of the abnormal uptake was reported in patients undergoing bone scintigraphy, and a disappearance of localized bone oedema was observed on MRIs from 12 treated patients”
Corrado, A., Colia, R. and Cantatore, F. P. (2017) ‘Neridronate: From Experimental Data to Clinical Use’, Clinical Medicine Insights: Therapeutics. doi: 10.1177/1179559X17732971.
How does it work?
CRPS Treatment is a Division of Medical Tourism Italy.
The process is therefor the same for the general Medical Tourism Italy patient; each online consultation and contact with our Personal Health Planner is completely free of charge, and you’ll get all the information you need to plan your therapy trail accordingly to your needs. After you’re settled with the kind of package you’d like to book, the hospitality solution that works best for you and all the details about your stay, the only thing you have to take care of on your own is booking the flights. We choose to work this way in the Patient’s interest.
We know that getting the best treatment abroad for your condition is expensive, and we want our patients to be able to save as much as possible if they so wish; as the plane fares are something constatly changing, we let our patients choose which airline to get and to which airport to arrive to (Verona, Treviso or Venice). From there on, we’ll take care of everything.
The Personal Health Planner will come and pick you up at the Airport, escort you to your Hotel, make sure that everything is up to your liking, drive you wherever you need to go, they will come with you to the therapies and hospital visits and you’ll not be left alone; the Personal Health Planner will be your interpreter throughout all your stay and even afterwards for a 6 months Followup included in the price.
For the CRPS Treatment specificially, the procedure is as follow:
- Visit in the Hospital with the CRPS Specialist
- Administering of the I.V. infusions of Neridronate
- Administering if needed of the pain medications
- Rehabilitaition and Physical Therapy with the designed specialist
- Rest and Recovery
- Tourism with the Personal Health Planner, if you so wish
- Light Therapy with Bioptron technology
More Scientific Data on Neridronate for CRPS
“Clinical case: A 23 years old man, from Pakistan, was admitted to our medical division with a 6 months history of left foot pain resistant to analgesics, causing inability to move and a previous hospital admission. Patient’s clinical history was unremarkable except for a 9 months earlier scvooter fall with left foot traumatism.
Just from the beginning, the pain seemed disproportionate in time and degree to anamnestic event and clinical-instrumental findings. Physical exam showed allodynia, darkening skin and trophic changes of the foot. Blood tests for inflammatory or autoimmunity
markers were negative. X-rays excluded fractures. US showed edema of subcutaneous tissue, which was confirmed with a foot MRI. On this basis, assuming a case of algodistrophy, a triplephase bone scintigraphy was performed with evidence of minor radio-tracer uptake in corrispondence of localized patchy left foot’s bone.
After a diagnosis of algodistrophy, a combined theraphy with painkillers and neridronate (a biphosphonate) was started. This allowed initial improvement and the discharge of the patient.”
More than twelve influential Scientific Research studies available
On our specifically designed page “www.crpsneridronate.com” you can find more than 12 external links to official Medical Journals and researches from several Scientific Sources that we have gathered for you. Here you’ll be able to see how Neridronate has been proven by many European studies to be the treatment of election for CRPS / RSD / Algodistrophy.
Italy is at the moment the only Country able to deliver effective application of the Therapy including not simply the infusions, but all the side therapies and the patient care needed to aim to the goal, a dramatic change in the quality of life if remission is not achiavable.
Get in touch with a Personal Health Planner today to start your journey back to a normal life.